Trade Vir Biotechnology VIR

VirBiotechnology live chart

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

VirBiotechnology news

Mga pinakabagong balita

Ipakita nang marami
Emma Rose 2025 Sep 19, 15:20

Federal Reserve Reform on the Horizon: Price Stability Act Sparks Debate on Central Bank's Mission

Ava Grace 2025 Sep 19, 14:20

Market Review: Fed Rate Cut and Global Economic Trends

Noah Lee 2025 Sep 19, 11:20

US Senators Target Russian Energy Exports with 'Shadow Fleet' Sanctions

Sophia Claire 2025 Sep 19, 04:20

Bank of Japan Holds Rates Steady, Plans to Start Selling ETFs

Liam James 2025 Sep 18, 15:20

Hong Kong Gold Theft Recovered: A Sign of a Growing Global Trend?

Ava Grace 2025 Sep 18, 15:20

US Initial Jobless Claims Fall: A Rebound or a Sign of Stability?

Sophia Claire 2025 Sep 18, 14:20

White House Reacts to Fed Rate Cut: Implications and Analysis

Sophia Claire 2025 Sep 18, 13:20

Swiss Gold Exports to US Plunge Amid Tariff Confusion

Info

Spread

0.05

Spread (%)

0.9728 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagsasara

Lunes

13:31 - 19:59

Martes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Biyernes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

719587072

Natitirang Pagbabahagi

138916426

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

Araw ng Pag-alis ng Karapatan sa Dividend

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-4.01

Alamin ang Higit Pa Tungkol sa Instrumentong ito

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Mga kaugnay na instrumento

view_all_instruments

latest_education_articles

Ipakita nang marami
Trustpilot